

Generic Name: Nifurtimox

Preferred: N/A

Therapeutic Class or Brand Name: Lampit®

Non-preferred: N/A

Applicable Drugs (if Therapeutic Class): N/A

Date of Origin: 2/2/2021

GPI Code: 164000550003

Date Last Reviewed / Revised: N/A

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I - IV are met)

- I. Documented diagnosis of one of the following conditions A, B or C and must meet criteria listed under applicable diagnosis:
 - A. **Chagas Disease – Pediatrics** (American Trypanosomiasis), caused by *Trypanosoma cruzi* (must meet all)
 1. Pediatrics with age less than 18 years old.
 2. Weight \geq 2.5 kg.
 3. Dose does not exceed 20 mg/kg/day.
 - B. **Chagas Disease – Adults** (American Trypanosomiasis), caused by *Trypanosoma cruzi* (**Off-Label**) (must meet all)
 1. Adults \geq 18 years old.
 2. Dose does not exceed 10 mg/kg/day.
 - C. **West African Trypanosomiasis**, caused by *Trypanosoma brucei gambiense* (**Off-Label**) (must meet all for infants, adolescents, and adults).
 1. Suspected or confirmed CNS involvement (late-stage infection).
 2. Used in combination with eflornithine.
 3. Dose does not exceed 15 mg/kg/day.
 4. For infants, children, and adolescents.
- II. Prescribed by or in consultation with an infectious disease specialist.

EXCLUSION CRITERIA

- Hypersensitivity to nifurtimox or any component of the formulation; alcohol consumption during treatment.

OTHER CRITERIA

CONFIDENTIAL & PROPRIETARY, VENTEGRA, INC.

www.ventegra.com

DISCLAIMER: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.

- CNS effects: May cause muscle weakness or tremors, which may impair physical abilities; patients must be cautioned about performing tasks such as operating machinery or driving if weakness or tremors occur.
- GI effects: Loss of appetite and nausea/vomiting leading to weight loss have been reported. Monitor body weight every 2 weeks during treatment and adjust dosage based on weight as needed.
- Hypersensitivity reaction: Hypersensitivity reactions, sometimes accompanied by angioedema (including laryngeal or facial edema), dyspnea, hypotension, pruritus, rash, or other severe skin reactions, have been reported. The hypersensitivity may be due to nifurtimox or an immune response caused by Chagas disease during treatment. Discontinue use at the first sign of serious hypersensitivity.
- Peripheral neuropathy: Use has been associated with peripheral neuropathy; monitor for signs and symptoms during therapy

QUANTITY / DAYS SUPPLY RESTRICTIONS

- 30 mg and 120 mg tablets: Up to 30-day supply.

APPROVAL LENGTH

- **Authorization:** 1 year.
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

APPENDIX

- N/A

REFERENCES

1. Lampit® (Nifurtimox) [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; August 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213464s000lbl.pdf
2. Medispan.
3. Bern C. Chagas disease: Antitrypanosomal drug therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Available at: <http://www.uptodate.com>.
4. American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.